Secondary data from a clinical trial has indicated that daily supplements containing its Tocomin SupraBio tocotrienols ingredient improved liver health of 66.7 percent of participants. The results were said to be statistically significant compared to the control group.
“We are very excited about this potent effect of Tocomin SupraBio on NAFLD, and hope to publish this data soon,” said Carotech. “This is the first research that demonstrated that the palm tocotrienol complex (Tocomin SupraBio) is effective [against] non-alcoholic fatty liver, a condition which to date has no proven drug treatment.”
According to the company, the research has been accepted for presentation at the upcoming Liver Meeting of the American Association for the Study of Liver Diseases (ASSLD).